Observational study / 2006
Three patients with advanced cancers experienced unexpectedly long survival times following high-dose intravenous vitamin C therapy.
Clinical details of three well-documented cases of advanced cancer were examined in accordance with National Cancer Institute (NCI) Best Case Series guidelines, with tumour pathology verified by NCI pathologists. Patients had unexpectedly long survival times after receiving high-dose intravenous vitamin C therapy. The authors note that intravenous administration can achieve plasma concentrations capable of in vitro toxicity to cancer cells, warranting a reassessment of intravenous vitamin C in cancer treatment.
Shows an association, not proof of cause and effect.
- Study type
- Case series
- Who was studied
- 3 patients with advanced cancer confirmed by histopathologic review
- What was measured
- Survival time and clinical response following high-dose intravenous vitamin C
THE PAPER
Intravenously administered vitamin C as cancer therapy: three cases.
Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. CMAJ, 2006.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.